24/7 Market News Snapshot 18 November, 2024 – Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

November 18, 2024

DENVER, Colo., 18 November, 2024 (247marketnews.com) – (NASDAQ:ACRS) are discussed in this article.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is experiencing a notable surge in its stock price, having opened at $2.025 and rapidly climbing to $2.799, reflecting an impressive increase of over 36.54%. This strong performance follows a prior session close at $2.050, signaling robust investor interest with a current trading volume of 3.79 million shares. The significant uptick in share value comes as Aclaris announces a strategic advancement in its portfolio, having secured an exclusive license agreement to develop BSI-045B and BSI-502, innovative biologic therapies licensed from Biosion, Inc.

This agreement reinforces Aclaris’ ambition to expand its footprint in the immunology sector, enhancing its pipeline of drug candidates aimed at addressing critical unmet needs in immuno-inflammatory diseases. BSI-045B, a promising clinical-stage anti-TSLP monoclonal antibody, has shown compelling safety and efficacy results in Phase 2a trials for atopic dermatitis. BSI-502, a breakthrough pre-clinical bispecific antibody targeting both TSLP and IL4R, presents a novel dual-action approach to mitigate inflammation, complementing Aclaris’ existing ITK inhibitor portfolio.

Dr. Neal Walker, Interim CEO of Aclaris, remarked that the transaction signifies a key milestone in the company’s evolution, propelling its capacity to deliver innovative treatment options. Additionally, Aclaris has bolstered its leadership team with the addition of Hugh Davis, Ph.D., as President and Chief Operating Officer, along with Steven Knapp, PharmD, as Executive Vice President, Head of Regulatory & Quality. Their combined expertise will be instrumental as the company advances its strategic initiatives and clinical programs.

Aclaris plans to host a conference call to elaborate on this significant development and provide insights into its corporate strategy, positioning itself as a pioneering entity in the biopharmaceutical landscape with a strong commitment to enhancing patient outcomes globally.

Related news for (ACRS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.